183 related articles for article (PubMed ID: 27965050)
21. Targeting catalase but not peroxiredoxins enhances arsenic trioxide-induced apoptosis in K562 cells.
Song LL; Tu YY; Xia L; Wang WW; Wei W; Ma CM; Wen DH; Lei H; Xu HZ; Wu YL
PLoS One; 2014; 9(8):e104985. PubMed ID: 25115845
[TBL] [Abstract][Full Text] [Related]
22. Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells.
Chiu HW; Tseng YC; Hsu YH; Lin YF; Foo NP; Guo HR; Wang YJ
Cancer Lett; 2015 Jan; 356(2 Pt B):762-72. PubMed ID: 25449439
[TBL] [Abstract][Full Text] [Related]
23. Interaction between arsenic trioxide and human primary cells: emphasis on human cells of myeloid origin.
Binet F; Antoine F; Girard D
Inflamm Allergy Drug Targets; 2009 Mar; 8(1):21-7. PubMed ID: 19275690
[TBL] [Abstract][Full Text] [Related]
24. Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis.
Li Y; Zhu X; Gu J; Dong D; Yao J; Lin C; Huang K; Fei J
Cancer Sci; 2010 Apr; 101(4):948-54. PubMed ID: 20148895
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells.
Wang R; Xia L; Gabrilove J; Waxman S; Jing Y
Leukemia; 2013 Feb; 27(2):315-24. PubMed ID: 22751450
[TBL] [Abstract][Full Text] [Related]
26. Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma.
Lam SK; Li YY; Zheng CY; Ho JC
Int J Oncol; 2015 Jan; 46(1):113-22. PubMed ID: 25335113
[TBL] [Abstract][Full Text] [Related]
27. Resveratrol and arsenic trioxide act synergistically to kill tumor cells in vitro and in vivo.
Zhao XY; Yang S; Chen YR; Li PC; Dou MM; Zhang J
PLoS One; 2014; 9(6):e98925. PubMed ID: 24901647
[TBL] [Abstract][Full Text] [Related]
28. Arsenic Trioxide and Icariin Show Synergistic Anti-leukemic Activity.
Wang Z; Zhang H; Dai L; Song T; Li P; Liu Y; Wang L
Cell Biochem Biophys; 2015 Sep; 73(1):213-9. PubMed ID: 25721870
[TBL] [Abstract][Full Text] [Related]
29. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice.
Kinjo K; Kizaki M; Muto A; Fukuchi Y; Umezawa A; Yamato K; Nishihara T; Hata J; Ito M; Ueyama Y; Ikeda Y
Leukemia; 2000 Mar; 14(3):431-8. PubMed ID: 10720138
[TBL] [Abstract][Full Text] [Related]
30. The cytotoxicity of arsenic trioxide to normal hematopoietic progenitors and leukemic cells is dependent on their cell-cycle status.
Huang MJ; Hsieh RK; Lin CP; Chang IY; Liu HJ
Leuk Lymphoma; 2002 Nov; 43(11):2191-9. PubMed ID: 12533046
[TBL] [Abstract][Full Text] [Related]
31. Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL.
Wang T; Wen T; Li H; Han B; Hao S; Wang C; Ma Q; Meng J; Liu J; Xu H
Int J Nanomedicine; 2019; 14():5581-5594. PubMed ID: 31413564
[TBL] [Abstract][Full Text] [Related]
32. Arsenic trioxide-induced apoptosis of Hep-2 cell line through modulating intracellular glutathione (GSH) level.
Cheng B; Yang X; An L; Gao B; Liu X
Auris Nasus Larynx; 2010 Feb; 37(1):89-94. PubMed ID: 19574005
[TBL] [Abstract][Full Text] [Related]
33. Expanding the use of arsenic trioxide: leukemias and beyond.
Chen Z; Chen GQ; Shen ZX; Sun GL; Tong JH; Wang ZY; Chen SJ
Semin Hematol; 2002 Apr; 39(2 Suppl 1):22-6. PubMed ID: 12012319
[TBL] [Abstract][Full Text] [Related]
34. [Experimental study of the anti-tumor effect of arsenic trioxide or thalidomide alone and combination of both for treatment of myelodysplastic syndrome model].
Lu J; Jin J; Xu WL
Zhonghua Er Ke Za Zhi; 2006 Mar; 44(3):228-33. PubMed ID: 16624066
[TBL] [Abstract][Full Text] [Related]
35. A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system.
Lu Y; Han S; Zheng H; Ma R; Ping Y; Zou J; Tang H; Zhang Y; Xu X; Li F
Int J Nanomedicine; 2018; 13():5937-5952. PubMed ID: 30323584
[TBL] [Abstract][Full Text] [Related]
36. Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A.
Iriyama N; Yuan B; Hatta Y; Horikoshi A; Yoshino Y; Toyoda H; Aizawa S; Takeuchi J
Oncol Rep; 2012 Nov; 28(5):1875-82. PubMed ID: 22940758
[TBL] [Abstract][Full Text] [Related]
37. Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.
Ling S; Xie H; Yang F; Shan Q; Dai H; Zhuo J; Wei X; Song P; Zhou L; Xu X; Zheng S
J Hematol Oncol; 2017 Feb; 10(1):59. PubMed ID: 28241849
[TBL] [Abstract][Full Text] [Related]
38. Arsenic trioxide-induced cytotoxicity in A549 cells: The role of necroptosis.
Jamil M; Mohammadi-Bardbori A; Safa O; Nikpoor AR; Bakhtari A; Mokhtarinejad M; Zadeh SN; Shadboorestan A; Omidi M
Drug Res (Stuttg); 2023 Sep; 73(7):417-425. PubMed ID: 37230480
[TBL] [Abstract][Full Text] [Related]
39. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
40. Realgar (As4S4) nanoparticles and arsenic trioxide (As2O3) induced autophagy and apoptosis in human melanoma cells in vitro.
Pastorek M; Gronesova P; Cholujova D; Hunakova L; Bujnakova Z; Balaz P; Duraj J; Lee TC; Sedlak J
Neoplasma; 2014; 61(6):700-9. PubMed ID: 25150315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
